Why Do Western Governments Keep Folding to China? Nexperia Serves Up Another Example.
The Netherlands is the latest example of a country succumbing to China’s leadership position in critical supply chains.
Trump’s Question to Meat Packers — Where’s the Beef? — Opens Market Manipulation Investigation
If Argentina imports aren’t lowering supermarket beef prices, perhaps an investigation into the cartelization of the big, globalist meat packers will finally have an impact?
Senate Witnesses Discuss Reshoring and Making China’s Massive Biotech Ecosystem Less Attractive for Big Pharma
Witnesses at a Senate hearing on Wednesday, Oct. 29 titled “The Future of Biotech” discussed ways to facilitate reshoring and making it attractive to expand in the U.S. and conduct R&D here instead of in China.
At Senate Commerce, Bipartisan Support for Shipbuilding Industry. So What is Congress Waiting For?
There are very few things that Democrats and Republicans agree on. One of them is the need to support domestic shipbuilding beyond just military vessels.
GM Tops the List of “Most Exposed to China”
This year, GM swapped positions with Ford. GM is the most exposed to China while Ford has declined to No. 5.
CPA’s Jeff Ferry Teaches the Next Generation How to Rebuild American Industry
CPA’s chief economist emeritus, Jeff Ferry, has gone back to school in his semi-retirement years. This time, though, it was a speaking gig at the University of Florida’s new Semiconductor Institute in Gainesville.
CPA Economist Leads Rare Bipartisan Push to Fix America’s Generic Drug Crisis
CPA Economist Andrew Rechenberg gave his testimony and answered questions in a four- panelist hearing. It was arguably the most agreeable hearing in years. A bipartisan consensus on America’s generic drug supply chain is nearly fully formed now.
Pharmaceutical 232 Must Cover Generic Drugs to Fulfill President’s Promise of Reshoring Essential Medicine Production
The Trump administration’s Section 232 investigation into pharmaceutical imports is reportedly close to being final. The final investigation’s success will depend largely on whether or not the Commerce Department determines that there is a crisis in the generics industry — an issue that President Trump highlighted back in 2023.
China Now Producing Dozens of Drugs Below Market Price – Dumping Them Globally is Next Move
As proof that no company can match China on price, Chinese producers of active pharmaceutical ingredients (APIs) and the key starting materials (KSMs) used to make them are slashing prices by up to 50%. Not even low-cost India – one of the largest importers of Chinese KSMs – can compete at those levels.
Ethan Allen CEO Explains How Company Will Manage Tariffs; Warns More of Services Inflation
For the second time in less than two months, the CEO of a publicly traded company admitted that tariff cost burdens will not be passed down fully, if at all, to consumers. With one CEO saying tariffs were too low.
